Immune checkpoint inhibitors as adjuvant therapy in patients with completely resected nonsmall cell lung cancer.

ABSTRACT

PURPOSE OF REVIEW The purpose of the review is to summarize the current status of immune checkpoint inhibitors as adjuvant therapy in patients with resected nonsmall cell lung cancer (NSCLC). RECENT FINDINGS: The IMpower010 phase 3 trial demonstrated improved disease-free survival and, in case of PD-L1 at least 50%, also improved overall survival for atezolizumab compared to best supportive care among patients with completely resected stage II-IIIA NSCLC. The PEARLS/KEYNOTE-091 trial showed increased disease-free survival for pembrolizumab among patients with stage IB-IIIA NSCLC. Trials with nivolumab and durvalumab are ongoing. SUMMARY: Atezolizumab or pembrolizumab have become options for adjuvant therapy in patients with completely resected NSCLC.